Introduction: Retention in HIV care and adherence to antiretroviral therapy (ART) during pregnancy and postpartum for women living with HIV (WLWH) are necessary to optimize health outcomes for women and infants. The objective of this study was to evaluate the impact of two evidenced-based behavioural interventions on postpartum adherence and retention in WLWH in Kenya. Methods: The Mother-Infant Visit Adherence and Treatment Engagement (MOTIVATE) study was a cluster-randomized trial enrolling pregnant WLWH from December 2015 to August 2017. Twenty-four health facilities in southwestern Kenya were randomized to: (1) standard care (control), (2) text-messaging, (3) community-based mentor mothers (cMM) or (4) text-messaging and cMM. Primary outcomes included retention in care and ART adherence at 12 months postpartum. Analyses utilized generalized estimating equations and competing risks regression. Per-protocol analyses examined differences in postpartum retention for women with high versus low levels of exposure to the interventions. Results: We enrolled 1331 pregnant WLWH (mean age 28 years). At 12 months postpartum, 1140 (85.6%) women were retained in care, 96 women (7.2%) were lost-to-follow-up (LTFU) and 95 (7.1%) were discontinued from the study. In intention-to-treat analyses, the relative risk of being retained at 12-months postpartum was not significantly higher in the intervention arms versus the control arm. In time-to-event analysis, the cMM and text arm had significantly lower rates of LTFU (hazard ratio 0.44, p = 0.019). In per-protocol analysis, the relative risk of 12-month postpartum retention was 24–29% higher for women receiving at least 80% of the expected intervention compared to the control arm; text message only risk ratio (RR) 1.24 (95% confidence interval [CI] 1.16–1.32, p<0.001), cMM only RR 1.29 (95% CI 1.21–1.37, p<0.001) and cMM plus text RR 1.29 (1.21–1.37, p<0.001). Women LTFU were younger (p<0.001), less likely to be married (p<0.001) and more likely to be newly diagnosed with HIV during pregnancy (p95% of pills taken since last clinic visit), fair (85–94%) or poor (95% of women reported good adherence throughout the study, this was compared versus combined fair or poor adherence. Secondary outcomes included viral suppression and infant outcomes. Viral load was added as a secondary measurement of adherence after routine viral load monitoring was introduced in Kenya after the study launched, and was obtained through health records. Per the Kenya National ART guidelines, viral load was obtained by clinic providers after 6 months of ART for those newly initiating (or at time of pregnancy identification for those already on ART) and every 6 months until cessation of breastfeeding [22]. Those with viral load <1000 copies/ml were considered virally suppressed. Retention in care at 12 months postpartum was defined as the proportion of women who had an HIV care visit within 90 days at 12 months after delivery. Women with documented transfer to another clinic, which required an official transfer letter, were considered retained in care. Women who died, experienced a pregnancy loss or child death, or withdrew were discontinued from the study and their data were used up until study discontinuation. The study was powered based on estimated differences in proportions of maternal ART adherence and retention in the intervention versus the control arms at 12 months postpartum accounting for clustering as previously reported [19, 27]. We estimated a baseline ART adherence rate of 55% based on pre‐universal ART rates found in the literature for pregnant women in SSA at the time of study design [28] and a baseline retention in care rate of 48% based on trial data from a study of service integration conducted in the same region in Kenya [29]. We powered our study to be able to detect a 25% absolute increase due to each intervention individually. To achieve 80% power for both outcomes with a conservative (high) intra‐cluster correlation coefficient of 0.12 and an average of 70 women sampled per community, we calculated 20 sites, 5 in each arm with a target sample size of 1336 women (334 women per arm) would be needed. Descriptive analyses summarized characteristics of participants and assessed frequency distributions of variables. Analyses of primary outcomes of maternal ART adherence and maternal retention in care (dichotomous variables) compared proportions between intervention and control groups using cluster adjusted two‐sided chi square tests. Given the clustered study design, generalized estimating equations (GEEs) were used to test for differences of interest in univariable and multivariable models, adjusted for relevant covariates identified as differing across study arms at baseline with p≤0.05, using a logit link. Secondary outcomes, such as maternal viral load suppression (80% of expected intervention dose received) versus low levels of exposure to the interventions, adjusted for gestational age at enrolment to the study. For the PP analyses, a level of completion of 80% of the intervention received was selected a priori as this was considered by the research team to be the minimal adequate dose of the interventions. Although there is no standard recommended cut‐off in the literature for the dose of multi‐session interventions received to be used in PP analyses, “clinical” judgement of an adequate dose is one accepted approach [30]. All analyses were done using Stata 15 Software [31]. All women enrolled in the study provided written informed consent. The study was approved by the Kenya Medical Research Institute, University of Alabama at Birmingham and the University of Colorado, Denver Institutional Review Boards.